OSTX Key Statistics, Chart & Performance
The current stock price of OSTX is 1.92 USD. In the past month the price increased by 5.49%. In the past year, price increased by 2.13%.
OSTX Latest News, Press Relases and Analysis
OSTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About OSTX
Company Profile
OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.
Company Info
OS THERAPIES INC
15825 Shady Grove Road, Suite 135
Rockville MARYLAND US
Employees: 4
Phone: 14102977793
OS THERAPIES INC / OSTX FAQ
Can you describe the business of OS THERAPIES INC?
OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.
What is the current price of OSTX stock?
The current stock price of OSTX is 1.92 USD. The price increased by 5.49% in the last trading session.
Does OS THERAPIES INC pay dividends?
OSTX does not pay a dividend.
What is the ChartMill rating of OS THERAPIES INC stock?
OSTX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of OS THERAPIES INC (OSTX)?
OS THERAPIES INC (OSTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.88).
Can you provide the growth outlook for OS THERAPIES INC?
The Revenue of OS THERAPIES INC (OSTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of OSTX stock?
OS THERAPIES INC (OSTX) has a market capitalization of 67.60M USD. This makes OSTX a Micro Cap stock.
OSTX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to OSTX. When comparing the yearly performance of all stocks, OSTX is a bad performer in the overall market: 69.17% of all stocks are doing better.
OSTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OSTX. The financial health of OSTX is average, but there are quite some concerns on its profitability.
OSTX Financial Highlights
Over the last trailing twelve months OSTX reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS decreased by -174.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -226.24% | ||
| ROE | -430.26% | ||
| Debt/Equity | 0 |
OSTX Forecast & Estimates
10 analysts have analysed OSTX and the average price target is 13.01 USD. This implies a price increase of 577.34% is expected in the next year compared to the current price of 1.92.
For the next year, analysts expect an EPS growth of 34.61% and a revenue growth -100% for OSTX